吡哌酸滴丸与氯霉素滴耳液治疗化脓性中耳炎的比较

目的：比较吡哌酸滴丸与氯霉素滴耳液治疗化脓性中耳炎的疗效。方法：化脓性中耳炎３０例（男性１９例，女性１１例；年龄３２±ｓ１７ａ），用吡哌酸滴丸１～２丸放至鼓膜穿孔处，每日换药１次；同期用氯霉素滴耳液治疗２９例作对照，疗程均１４ｄ。结果：吡哌酸滴丸组和氯霉素滴耳液组总有效率分别为９３％和７０％（Ｐ＜０．０５），治愈天数分别为５．６±２．８ｄ和１２．０±２．８ｄ（Ｐ＜０．０１）。细菌清除率分别为６２％和２８％；细菌阴转率分别为８７％和４３％（Ｐ＜０．０１）。结论：吡哌酸滴丸是治疗化脓性中耳炎较满意的药物。     

吡哌酸滴丸与氨霉素滴耳液治疗化脓性中耳炎的比较

目的：比较吡哌酸滴丸与氯霉素滴耳液治疗化脓性中耳炎的疗效。方法：化脓性中耳炎３０例（男性１９例，女性１１例，年龄３２±ｓ１７ａ），用吡哌酸滴丸１￣２丸放至鼓膜穿孔处，每日换药１次；同期用氯霉素滴耳液治疗２９例作对照，疗程均１４ｄ。结果：吡哌酸滴丸组和氯霉素滴耳液组总有效率分别为９３％和７０％（Ｐ〈０．０１）。细菌清除率分别为６２％和２８％，细菌阴转率分别为８７％和４３％（Ｐ〈０．０１）。结论：吡哌     

利福平(0.1%)液治疗慢性化脓性中耳炎

目的：观察０ ．１ ％ 利福平液治疗化脓性中耳炎的效果。方法：１５０ 例慢性单纯性化脓性中耳炎病人（ 男性１１８ 例,女性３２ 例,年龄２４ ａ ±ｓ ８ ａ） 。随机分为 Ａ, Ｂ, Ｃ ３ 组,每组５０ 例。分别用０ ．０５ ％利福平、０ ．１ ％ 利福平和０ ．２５ ％ 氯霉素眼药水进行滴耳治疗。每日滴药２ 次,每次３ ～５ 滴,５ ｄ 为一个疗程,共１ ～３ 个疗程。结果：０ ．１ ％ 利福平组总有效率为９６ ％ ;０ ．０５ ％ 利福平组为６０ ％ ;０ ．２５ ％ 氯霉素组为５４ ％ 。０ ．１ ％ 利福平组与另外２ 组比较差异有非常显著意义（ Ｐ＜ ０ ．０１） 。结论：０ ．１ ％ 利福平液用于治疗慢性单纯性化脓性中耳炎具有疗效好、安全、方便、经济等特点。     

氧氟沙星与头孢氨苄治疗卡他性中耳炎的比较

目的：观察氧氟沙星治疗鼻咽炎引起的卡他性中耳炎的疗效。方法：卡他性中耳炎病人５５例（男性３７例，女性１８例，年龄３２±ｓ１２ａ），随机分氧氟沙星治疗组５５例（６３耳），用氧氟沙星０．２ｇ，ｐｏ，ｔｉｄ。头孢氨苄对照组４２例（４７耳），用头孢氨苄０．５ｇ，ｐｏ，ｔｉｄ。结果：治疗组总有效率为９７％，对照组的总有效率为８１％（Ｐ＜０．０５）。２组用药天数分别为４．５±１．５ｄ与７±４ｄ（Ｐ＜０．０１）。副作用轻微。结论：氧氟沙星治疗急、慢性卡他性中耳炎的疗效满意。     

氧氟沙星与头孢氨苄治疗卡他性中耳炎的比较

目的：观察氧氟沙星治疗鼻咽炎引起的卡他性中耳炎的疗效。方法：卡他性中耳炎病人５５例（男性３７例，女性１８例，年龄３２±ｓ１２ａ）随机分氧氟沙治疗组５５例（６３耳），用氧氟沙星０．２ｇ，ｐｏ，ｔｉｄ，头孢氨苄对照组４２例（４７耳），用头孢氨苄０．５ｇ，ｐｏ，ｔｉｄ，结果；治疗组总有效率为９７％，对照组有的总有效率为８１％（Ｐ〈０．０５），２组用药天数分别为４．５±１．５ｄ与７±４ｄ（Ｐ〈０．０１），     

依诺沙星治疗慢性化脓性中耳炎112例疗效观察

依诺沙星治疗慢性化脓性中耳炎１１２例疗效观察王志朝，汤韧，姜加维（广州军区武汉总医院，武汉４３００７０）国产依诺沙星制成０．４％滴耳液治疗慢性化脓性中耳炎１１２例。对照组（氯霉素滴耳液）５０例。治疗组用依诺沙星滴耳液４～６滴，每次耳浴约５分钟，Ｂｉｄ...     

硫必利和山莨菪碱治疗血管性头痛

血管性头痛２２０例，分为４组，甲组１４０例（男性４５，女性９５，年龄３５±ｓ２１ａ），服硫必利０．１ｇ加山莨菪碱５ｍｇ，ｔｉｄ；乙组４０例（男性２０，女性２０，年龄３５±４ａ），服硫必利０．１ｇ，ｔｉｄ；丙组２０例（男性１０，女性１０，年龄４２±１１ａ），服山莨菪碱５ｍｇｔｉｄ；丁组２０例（男性５，女性１５，年龄４７±８ａ），服维生素Ｂ１１０ｍｇ，ｔｉｄ。４组均连续用药７ｄ。结果４组总有效率分别为９６％，４８％，４５％和５％，甲组疗效最好，Ｐ＜０．０１。     

表皮生长因子治疗鼻中隔粘膜糜烂性鼻出血

目的：观察表皮生长因子治疗鼻中隔粘膜糜烂性鼻出血的疗效。方法：治疗组６２例（男性２９例，女性３３例；年龄３５±ｓ６ａ）用０．２％表皮生长因子明胶海绵敷贴在鼻中隔的糜烂面上，并用该药液滴鼻，每次４滴，ｑｉｄ×１０ｄ。对照组３０例（男性１４例，女性１６例，年龄３２±５ａ）用０．２５％氯霉素明胶海绵敷贴，并用此药滴鼻，每次４滴，ｑｉｄ×１０ｄ。结果：治疗组出血停止，鼻腔干燥，刺痛感消失，粘膜恢复正常的平均天数及复发率均低于对照组（Ｐ＜０．０１），未见不良反应。结论：表皮生长因子可作为治疗鼻中隔粘膜糜烂性鼻出血的满意制剂。     

环丙沙星治疗化脓性中耳炎

观察环丙沙星对中耳炎的疗效。方法：配制０．５％环丙沙星滴耳剂，治疗慢性及急性中耳炎分别４１耳及１５耳，共４７人，其中男性３０例，女性１７例，年龄１０±ｓ９ａ。结果：急性全部治愈；慢性治愈率７８％，未出现副作用。结论：用环丙沙星滴耳剂治疗急、慢性中耳炎疗效肯定，值得试用。     

环丙沙星治疗化脓性中耳炎

目的：观察环丙沙星对中耳炎的疗效。方法：配制０．５％环丙沙星滴耳剂，治疗慢性及急性中耳炎分别４１耳及１５耳，共４７人，其中男性３０例，女性１７例，年龄１０±ｓ９ａ。结果：急性全部治愈；慢性治愈率７８％，未出现副作用。结论：用环丙沙星滴耳剂治疗急、慢性中耳炎疗效肯定，值得试用。     

Ofloxacin otic solution: a review of its use in the management of ear infections.

Ofloxacin is a synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. Ofloxacin has been formulated as a 0.3% otic solution for the treatment of ear infections. Topical administration of ofloxacin otic solution 0.3% produces very high concentrations of drug in the ear, thus broadening the spectrum of activity of ofloxacin greatly, to cover most common ear pathogens. Results of clinical trials indicate that ofloxacin otic solution 0.3% is as effective as topical neomycin/polymixin B/hydrocortisone preparations in the treatment of otitis externa (clinical cure rate >80% in adults and >95% in children for both treatments) and oral amoxicillin/clavulanic acid in the treatment of otitis media in the presence of tympanostomy tubes in children (clinical cure rates 76 and 69% for ofloxacin and amoxicillin/clavulanic acid, respectively). It is also effective in the treatment of chronic suppurative otitis media in adolescents and adults with perforated tympanic membranes (75 to 91% clinical cure rate). Because of the limited systemic absorption after topical administration, ofloxacin otic solution 0.3% is well tolerated. Adverse events were usually classed as mild to moderate, with < or =2% considered severe. The most frequent adverse events were bitter taste (5%), primarily in patients with non-intact tympanic membranes, and pruritis (2%). The incidence of adverse events with ofloxacin otic solution 0.3% was similar to that with other ototopical preparations and significantly less than that with oral amoxicillin/clavulanic acid. Unlike comparative ototopical antibacterials, ofloxacin was not ototoxic or chondrotoxic in animal studies. In addition, no ototoxicity was detected in clinical studies in humans. CONCLUSIONS: Ofloxacin otic solution 0.3% is clinically effective in the treatment of otitis externa and otitis media in patients with tympanic membrane perforations or tympanostomy tubes. The high concentrations achieved with this ototopical solution render it active against a broad spectrum of organisms. It is well tolerated, avoiding many systemic adverse events, and is not associated with ototoxicity. As the first ototopical agent approved for use in patients with non-intact tympanic membranes, ofloxacin otic solution 0.3% provides a valuable advantage over current treatment alternatives.     

A benefit-risk assessment of ofloxacin otic solution in ear infection.

Ofloxacin is a fluoroquinolone antibacterial with potent bactericidal activities and the topical otological preparation of this drug has been clinically utilised since the late 1980s. The rate of eradication with ofloxacin ranges from 83.3% to 100% for all pathogens commonly isolated from middle ear effusions in cases of otitis media and otitis externa. Despite the significant length of its usage, emergence of resistant pathogens has been rarely encountered in clinical trials; only two strains of Pseudomonas aeruginosa have been documented with decreased susceptibility to ofloxacin following the use of the otic solution.Ear infections, including otitis externa, chronic suppurative otitis media and otorrhoea associated with tympanostomy tubes, are common problems in clinical practice. The potential complications associated with ear infection can be otological, extratemporal, or even psychosocial. They are sometimes fatal and the effect can be long-lasting and detrimental. The use of an effective topical antibacterial with high cost-effectiveness is definitely warranted. As regards various clinical aspects, including overall success rate, symptomatic relief of otalgia and otorrhoea, ofloxacin otic solution was found to be more effective than comparator agents, be it a topical antibacterial, a systemic antibacterial or combination drugs.The systemic absorption of fluoroquinolones is minimal after topical application. Ofloxacin otic solution 0.3% has been shown to have a low rate of adverse drug reactions. Adverse reactions to ofloxacin otic solution were generally mild. The lack of ototoxic effect from ofloxacin eardrops, even in the concentration higher than 0.3%, has been demonstrated in animal studies. In the clinical setting, no increase in bone-conduction threshold has been shown after the treatment of topical ofloxacin otic solution. There have not been any reports of ototoxicity with ofloxacin otic solution since its approval.To conclude, ofloxacin otic solution 0.3% is clinically effective in the treatment of otitis externa and chronic suppurative otitis media in particular with respect to the overall cure rate, relief of otalgia and otorrhoea. It is well tolerated, with minimal adverse effects. It is not associated with any ototoxicity both experimentally and clinically.     

氧氟沙星滴耳液配合泼尼松龙鼓室注射治疗分泌性中耳炎疗效观察

目的探讨鼓室内注入0.3%氧氟沙星滴耳液配合泼尼松龙治疗分泌性中耳炎（SOM）的效果。方法对140例（160耳）SOM患者（治疗组）行鼓膜穿刺,并向鼓室内注射0.3%氧氟沙星滴耳液和泼尼松龙;对照组144例（160耳）鼓室内注射泼尼松龙。随访2个月,对两组的总有效率和治疗次数进行比较。结果治疗组总有效率为97.5%,对照组总有效率为90.0%,两组比较,χ2=7.68,P〈0.01;两组治疗次数比较,χ2=104.532,P〈0.01。结论 0.3%氧氟沙星滴耳液配合泼尼松龙鼓室内注射对SOM患者有明显疗效。     

氧氟沙星、依诺沙星和诺氟沙星治疗伤寒疗效比较

用氧氟沙星(65例)0.6g/d,依诺沙星(57例)0.6g/d,诺氟沙星(65例)0.8-1.2g/d治疗伤寒。开始退热时间依次为2.6±1.0d,3.8±1.2d,5.3±1.8d,热退到正常时间4.4±1.4d,7.6±2.6d,10±3d,疗程7.5±1.1d,10.6±2.6d,13±3d,有效率依次为100％,90％,63％。结果提示:氧氟沙星疗效显著优于依诺沙星和诺氟沙星,是临床治疗伤寒的满意药物。     

桃金娘油辅助治疗C型鼓室导抗图的分泌性中耳炎

目的 :观察桃金娘油辅助治疗C型鼓室导抗图的分泌性中耳炎的疗效。方法 :将 92例 (112耳 )该病的病人随机分为 2组。治疗组 5 0例 (5 8耳 ) [男性 2 8例 ,女性 2 2例 ,年龄 (38±s 6 )a]在咽鼓管扩张再通鼓室注药 (地塞米松 +糜蛋白酶 )术的基础上 ,应用桃金娘油胶囊 30 0mg(儿童用 12 0mg) ,po ,tid× 15d。对照组 4 2例 (5 4耳 ) [男性 2 2例 ,女性 2 0例 ,年龄 (39± 5 )a]用三磷腺苷 (adeno sinetriphosphate)片 4 0mg(儿童用 2 0mg) ,po ,tid× 15d。结果 :治疗组的听力 ,耳鸣 ,耳堵塞感 ,鼓室图峰压值 ,随访 0 .5a的疗效稳定性均明显优于对照组 (P <0 .0 1) ,未见不良反应。结论 :桃金娘油是治疗C型鼓室导抗图的分泌性中耳炎有效、安全的辅助治疗药     

57例慢性化脓性中耳炎的临床治疗分析

目的观察慢性化脓性中耳炎患者的临床治疗效果。方法对于2009年1月至2011年6月在本院住院的57例慢性化脓性中耳炎患者进行治疗,根据不用的病理类型采取不同的方法进行治疗。结果 57例患者均获得随访,随访时间5~18个月,平均(12.3±2.1)个月;其中53耳经修补鼓膜后完全成活,成功率为92.9%,无穿孔发生;52耳听力提高10~15dB,占91.2%,3耳听力无改变;2耳听力轻度下降;听力提高总有效率为92.11%;患耳的听力能力治疗后较治疗前有明显提高(P<0.05)。结论不同类型的慢性化脓性中耳炎患者采用不同的治疗方法,其疗效显著,听力有明显先改善。     

氧氟沙星滴眼剂临床疗效评价

目的：评价氧氟沙星滴眼剂的临床疗效及其安全性。方法：眼疾病病人验证组１２１例（男性６３例,１００只眼,女性５８例,８８只眼,年龄３０ａ±ｓ２１ａ）,用伊犁哈萨克自治州友谊医院研制的０．３％氧氟沙星滴眼剂。对照组３９例（男性１５例,２２只眼,女性２４例,３５只眼,年龄３５ａ±１０ａ）,用日本参天制药株式会社生产的０．３％氧氟沙星滴眼剂。每次均１滴（约０．２ｍＬ）,ｔｉｄ。治疗开始后ｄ４,ｄ７及ｄ１４复诊。结果：验证组细菌性眼疾病总显效率为７１．３％,对照组为３２％（Ｐ＜０．０１）。结论：伊犁哈萨克自治州友谊医院研制的氧氟沙星滴眼剂对细菌性眼疾有明显治疗作用。     

甲泼尼龙治疗分泌性中耳炎33例

目的：评价甲泼尼龙治疗分泌性中耳炎的临床疗效和安全性。方法：65例(74耳)分泌性中耳炎的病人分为2组。试验组33例(37耳),其中男性17例,女性16例,年龄(36±s 5)a,应用甲泼尼龙16 mg,po,qd×3 d,3 d后改为8 mg,po,qd×3 d；3 d后改为4 mg,po,qd×3 d。对照组32例(37耳),男性15例,女性17例,年龄(35±4)a,应用地塞米松0.75 mg,po,tid×9 d。观察2组治疗后9 d和随访3 mo时的疗效和安全性。结果：治疗后9 d和随访3 mo时,2组气导平均听阈值和鼓室导抗图峰压值均下降,与治疗前比较差异非常显著(P＜0.01),其中试验组下降幅度大于对照组(P＜0.01)。试验组有效率分别为97%和91%,对照组的有效率分别为84%和72%,2组疗效比较差异显著,试验组优于对照组(P＜0.05)。试验组不良反应发生率9%,低于对照组的22%,但差异无显著意义(P＞0.05)。结论：甲泼尼龙治疗分泌性中耳炎有效、安全。